CT-P13 SC (Infliximab)

Phase 3Monoclonal antibody

CCelltrion

CT-P13 SC (Infliximab) is one of 66 biologic programs targeting Rheumatoid Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Cimzia

UCB

Preclinical

30 3

Simponi

Johnson & Johnson

Preclinical

19 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

CT-P13 SC (Infliximab)

CCelltrion

Phase 3

1 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Celexa

AbbVie

Preclinical

1 9

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Crohn's Disease1 trial

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

Completed·CCelltrion·Phase 3·NCT03945019·396 enrolled

Ulcerative Colitis1 trial

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

Completed·CCelltrion·Phase 3·NCT04205643·548 enrolled

Infliximab1 trial

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

Completed·CCelltrion·Phase 1·NCT03446976·218 enrolled

Rheumatoid Arthritis1 trial

A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

Active, not recruiting·CCelltrion·Phase 3·NCT06738719·192 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CT-P13 SC (Infliximab). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CT-P13 SC (Infliximab) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CT-P13 SC (Infliximab). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celltrion company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: CCelltrion

CT-P13 SC (Infliximab)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Crohn's Disease1 trial

Ulcerative Colitis1 trial

Infliximab1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News